Long-term efficacy of dexamethasone treatment via tympanic antrum catheterization for intractable Meniere's disease
ObjectiveTo explore the long-term efficacy and safety of dexamethasone treatment via tympanic antrum catheterization (TAC) in intractable Meniere's disease (MD).MethodsIn this retrospective analysis, 60 unilateral intractable MD patients treated with TAC in our hospital from January 2020 to Aug...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2022.1056724/full |
| _version_ | 1797987419791818752 |
|---|---|
| author | Yafeng Lyu Yafeng Lyu Yafeng Lyu Jia Guo Jia Guo Jia Guo Xiaofei Li Xiaofei Li Xiaofei Li Huirong Jian Huirong Jian Huirong Jian Yawei Li Yawei Li Yawei Li Jing Wang Jing Wang Jing Wang Zhaomin Fan Zhaomin Fan Zhaomin Fan Haibo Wang Haibo Wang Haibo Wang Daogong Zhang Daogong Zhang Daogong Zhang |
| author_facet | Yafeng Lyu Yafeng Lyu Yafeng Lyu Jia Guo Jia Guo Jia Guo Xiaofei Li Xiaofei Li Xiaofei Li Huirong Jian Huirong Jian Huirong Jian Yawei Li Yawei Li Yawei Li Jing Wang Jing Wang Jing Wang Zhaomin Fan Zhaomin Fan Zhaomin Fan Haibo Wang Haibo Wang Haibo Wang Daogong Zhang Daogong Zhang Daogong Zhang |
| author_sort | Yafeng Lyu |
| collection | DOAJ |
| description | ObjectiveTo explore the long-term efficacy and safety of dexamethasone treatment via tympanic antrum catheterization (TAC) in intractable Meniere's disease (MD).MethodsIn this retrospective analysis, 60 unilateral intractable MD patients treated with TAC in our hospital from January 2020 to August 2020 were followed for 2 years. Fifty patients who underwent endolymphatic sac decompression (ESD) and 50 patients who accepted intratympanic steroids (ITS) were established as the control groups. Vertigo control, hearing level, tinnitus, aural fullness and functional level were assessed during the study.ResultsThe effective vertigo control rate of intractable MD patients with TAC treatment was 76.7% (46/60) after 2 years follow-up, with a complete control rate of 58.3% (35/60) and a substantial control rate of 18.3% (11/60). The vertigo control rate of TAC was comparable to that of ESD (χ2 = 0.313, p > 0.05), and significantly higher than that of ITS (χ2 = 4.380, p < 0.05). The hearing loss rate of these patients was 10.8% (4/37), which was not significantly different from the control groups (χ2 = 2.452, p > 0.05). The tinnitus improvement rate of patients with TAC was 56.7% (34/60), which was significantly higher than that of patients with ESD (χ2 =11.962, p < 0.001) and ITS (χ2 =15.278, p < 0.001). The aural fullness improvement rate in the TAC group was 56.7% (34/60), which was significantly higher than that in the ESD (χ2 = 11.962, p < 0.001) and ITS groups (χ2 = 5.635, p < 0.05). The functional level improvement rate in the TAC group was 71.7% (43/60), which was much higher than that in the ITS group (χ2 = 17.256, p < 0.001), but there was no significant difference between TAC and ESD (χ2 = 0.410, p > 0.05). No patients had complications or adverse reactions following TAC treatment.ConclusionDexamethasone treatment via TAC can effectively control vertigo attacks and improve related symptoms of intractable MD patients, providing valuable new insights into the treatment of MD. |
| first_indexed | 2024-04-11T07:48:23Z |
| format | Article |
| id | doaj.art-768bee72503a4e4b8d5519f314596eac |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-04-11T07:48:23Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-768bee72503a4e4b8d5519f314596eac2022-12-22T04:36:11ZengFrontiers Media S.A.Frontiers in Neurology1664-22952022-12-011310.3389/fneur.2022.10567241056724Long-term efficacy of dexamethasone treatment via tympanic antrum catheterization for intractable Meniere's diseaseYafeng Lyu0Yafeng Lyu1Yafeng Lyu2Jia Guo3Jia Guo4Jia Guo5Xiaofei Li6Xiaofei Li7Xiaofei Li8Huirong Jian9Huirong Jian10Huirong Jian11Yawei Li12Yawei Li13Yawei Li14Jing Wang15Jing Wang16Jing Wang17Zhaomin Fan18Zhaomin Fan19Zhaomin Fan20Haibo Wang21Haibo Wang22Haibo Wang23Daogong Zhang24Daogong Zhang25Daogong Zhang26Department of Otolaryngology-Head and Neck Surgery, Shandong Provincial ENT Hospital, Shandong University, Jinan, ChinaShandong Provincial Vertigo and Dizziness Medical Center, Jinan, ChinaLaboratory of Vertigo Disease, Shandong Institute of Otorhinolaryngology, Jinan, ChinaDepartment of Otolaryngology-Head and Neck Surgery, Shandong Provincial ENT Hospital, Shandong University, Jinan, ChinaShandong Provincial Vertigo and Dizziness Medical Center, Jinan, ChinaLaboratory of Vertigo Disease, Shandong Institute of Otorhinolaryngology, Jinan, ChinaDepartment of Otolaryngology-Head and Neck Surgery, Shandong Provincial ENT Hospital, Shandong University, Jinan, ChinaShandong Provincial Vertigo and Dizziness Medical Center, Jinan, ChinaLaboratory of Vertigo Disease, Shandong Institute of Otorhinolaryngology, Jinan, ChinaDepartment of Otolaryngology-Head and Neck Surgery, Shandong Provincial ENT Hospital, Shandong University, Jinan, ChinaShandong Provincial Vertigo and Dizziness Medical Center, Jinan, ChinaLaboratory of Vertigo Disease, Shandong Institute of Otorhinolaryngology, Jinan, ChinaDepartment of Otolaryngology-Head and Neck Surgery, Shandong Provincial ENT Hospital, Shandong University, Jinan, ChinaShandong Provincial Vertigo and Dizziness Medical Center, Jinan, ChinaLaboratory of Vertigo Disease, Shandong Institute of Otorhinolaryngology, Jinan, ChinaDepartment of Otolaryngology-Head and Neck Surgery, Shandong Provincial ENT Hospital, Shandong University, Jinan, ChinaShandong Provincial Vertigo and Dizziness Medical Center, Jinan, ChinaLaboratory of Vertigo Disease, Shandong Institute of Otorhinolaryngology, Jinan, ChinaDepartment of Otolaryngology-Head and Neck Surgery, Shandong Provincial ENT Hospital, Shandong University, Jinan, ChinaShandong Provincial Vertigo and Dizziness Medical Center, Jinan, ChinaLaboratory of Vertigo Disease, Shandong Institute of Otorhinolaryngology, Jinan, ChinaDepartment of Otolaryngology-Head and Neck Surgery, Shandong Provincial ENT Hospital, Shandong University, Jinan, ChinaShandong Provincial Vertigo and Dizziness Medical Center, Jinan, ChinaLaboratory of Vertigo Disease, Shandong Institute of Otorhinolaryngology, Jinan, ChinaDepartment of Otolaryngology-Head and Neck Surgery, Shandong Provincial ENT Hospital, Shandong University, Jinan, ChinaShandong Provincial Vertigo and Dizziness Medical Center, Jinan, ChinaLaboratory of Vertigo Disease, Shandong Institute of Otorhinolaryngology, Jinan, ChinaObjectiveTo explore the long-term efficacy and safety of dexamethasone treatment via tympanic antrum catheterization (TAC) in intractable Meniere's disease (MD).MethodsIn this retrospective analysis, 60 unilateral intractable MD patients treated with TAC in our hospital from January 2020 to August 2020 were followed for 2 years. Fifty patients who underwent endolymphatic sac decompression (ESD) and 50 patients who accepted intratympanic steroids (ITS) were established as the control groups. Vertigo control, hearing level, tinnitus, aural fullness and functional level were assessed during the study.ResultsThe effective vertigo control rate of intractable MD patients with TAC treatment was 76.7% (46/60) after 2 years follow-up, with a complete control rate of 58.3% (35/60) and a substantial control rate of 18.3% (11/60). The vertigo control rate of TAC was comparable to that of ESD (χ2 = 0.313, p > 0.05), and significantly higher than that of ITS (χ2 = 4.380, p < 0.05). The hearing loss rate of these patients was 10.8% (4/37), which was not significantly different from the control groups (χ2 = 2.452, p > 0.05). The tinnitus improvement rate of patients with TAC was 56.7% (34/60), which was significantly higher than that of patients with ESD (χ2 =11.962, p < 0.001) and ITS (χ2 =15.278, p < 0.001). The aural fullness improvement rate in the TAC group was 56.7% (34/60), which was significantly higher than that in the ESD (χ2 = 11.962, p < 0.001) and ITS groups (χ2 = 5.635, p < 0.05). The functional level improvement rate in the TAC group was 71.7% (43/60), which was much higher than that in the ITS group (χ2 = 17.256, p < 0.001), but there was no significant difference between TAC and ESD (χ2 = 0.410, p > 0.05). No patients had complications or adverse reactions following TAC treatment.ConclusionDexamethasone treatment via TAC can effectively control vertigo attacks and improve related symptoms of intractable MD patients, providing valuable new insights into the treatment of MD.https://www.frontiersin.org/articles/10.3389/fneur.2022.1056724/fullvestibular pluggingotolith dysfunctionMeniere's diseasedrop attacksemicircular canal plugging |
| spellingShingle | Yafeng Lyu Yafeng Lyu Yafeng Lyu Jia Guo Jia Guo Jia Guo Xiaofei Li Xiaofei Li Xiaofei Li Huirong Jian Huirong Jian Huirong Jian Yawei Li Yawei Li Yawei Li Jing Wang Jing Wang Jing Wang Zhaomin Fan Zhaomin Fan Zhaomin Fan Haibo Wang Haibo Wang Haibo Wang Daogong Zhang Daogong Zhang Daogong Zhang Long-term efficacy of dexamethasone treatment via tympanic antrum catheterization for intractable Meniere's disease Frontiers in Neurology vestibular plugging otolith dysfunction Meniere's disease drop attack semicircular canal plugging |
| title | Long-term efficacy of dexamethasone treatment via tympanic antrum catheterization for intractable Meniere's disease |
| title_full | Long-term efficacy of dexamethasone treatment via tympanic antrum catheterization for intractable Meniere's disease |
| title_fullStr | Long-term efficacy of dexamethasone treatment via tympanic antrum catheterization for intractable Meniere's disease |
| title_full_unstemmed | Long-term efficacy of dexamethasone treatment via tympanic antrum catheterization for intractable Meniere's disease |
| title_short | Long-term efficacy of dexamethasone treatment via tympanic antrum catheterization for intractable Meniere's disease |
| title_sort | long term efficacy of dexamethasone treatment via tympanic antrum catheterization for intractable meniere s disease |
| topic | vestibular plugging otolith dysfunction Meniere's disease drop attack semicircular canal plugging |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2022.1056724/full |
| work_keys_str_mv | AT yafenglyu longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT yafenglyu longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT yafenglyu longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT jiaguo longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT jiaguo longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT jiaguo longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT xiaofeili longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT xiaofeili longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT xiaofeili longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT huirongjian longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT huirongjian longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT huirongjian longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT yaweili longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT yaweili longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT yaweili longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT jingwang longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT jingwang longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT jingwang longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT zhaominfan longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT zhaominfan longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT zhaominfan longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT haibowang longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT haibowang longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT haibowang longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT daogongzhang longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT daogongzhang longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease AT daogongzhang longtermefficacyofdexamethasonetreatmentviatympanicantrumcatheterizationforintractablemenieresdisease |